Hypomagnesemia, chronic kidney disease and cardiovascular mortality: Pronounced association but unproven causation

Hemodialysis International

Volumn 18, Issue 4, 2014, Pages 730-739

  Dousdampanis, Periklis ^a   Trigka, Konstantina ^a   Fourtounas, Costas ^b  

^a Hemodialysis Unit Kyanos Stavros Patras   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Cardiovascular disease; Chronic kidney disease; Hemodialysis; Magnesium; Mortality; Peritoneal dialysis

Indexed keywords

INSULIN; MAGNESIUM;

ARTICLE; ATHEROSCLEROSIS; CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE COURSE; DYSLIPIDEMIA; END STAGE RENAL DISEASE; ENDOTHELIAL DYSFUNCTION; HEART ARRHYTHMIA; HEMODIALYSIS PATIENT; HOMEOSTASIS; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOMAGNESEMIA; HYPOTENSION; INFLAMMATION; INSULIN RESISTANCE; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAGNESIUM BLOOD LEVEL; MAGNESIUM DEFICIENCY; MORTALITY; NUTRITIONAL STATUS; OBSERVATIONAL STUDY; OXIDATIVE STRESS; ADVERSE EFFECTS; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; RENAL REPLACEMENT THERAPY;

CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; HUMANS; MAGNESIUM; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84926147515     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/hdi.12159     Document Type: Article

References (116)

1. Wolf FI, Trapani V. Cell (patho)physiology of magnesium. Clin Sci (Lond). 2008; 114:27-35.
2. Weglicki WB, Dickens BF, Wagner TL, Chmielinska JJ, Phillips TM. Immunoregulation by neuropeptides in magnesium deficiency: Ex vivo effect of enhanced substance P production on circulating T lymphocytes from magnesium-deficient mice. Magnes Res. 1996; 9:3-11.
3. Malpuech-Brugère C, Nowacki W, Daveau M, etal. Inflammatory response following acute magnesium deficiency in the rat. Biochim Biophys Acta. 2000; 1501:91-98.
4. Wei M, Esbaei K, Bargman J, Oreopoulos DG. Relationship between serum magnesium, parathyroid hormone, and vascular calcification in patients on dialysis: A literature review. Perit Dial Int. 2006; 26:366-373.
5. Walser M. Magnesium metabolism. Ergeb Physiol. 1967; 59:185-296.
6. Elin RJ. Magnesium metabolism in health and disease. Dis Mon. 1988; 34:161-218.
7. Musso CG. Magnesium metabolism in health and disease. Int Urol Nephrol. 2009; 41:357-362.
8. Sakaguchi Y, Shoji T, Hayashi T, etal. Hypomagnesemia in type 2 diabetic nephropathy: A novel predictor of end-stage renal disease. Diabetes Care. 2012; 35:1591-1597.
9. Eisenman K, Holley JLA. Higher magnesium dialysate concentration treats hypomagnesemia. Perit Dial Int. 2005; 25:604-605.
10. Ryan MP. Diuretics and potassium/magnesium depletion. Directions for treatment. Am J Med. 1987; 82:38-47.
11. Stevenson RN, Keywood C, Amadi AA, Davies JR, Patterson DL. Angiotensin converting enzyme inhibitors and magnesium conservation in patients with congestive cardiac failure. Br Heart J. 1991; 66:19-21.
12. Bo S, Pisu E. Role of dietary magnesium in cardiovascular disease prevention, insulin sensitivity and diabetes. Curr Opin Lipidol. 2008; 19:50-56.
13. Markaki A, Kyriazis J, Stylianou K, etal. The role of serum magnesium and calcium on the association between adiponectin levels and all-cause mortality in end-stage renal disease patients. PLoS ONE. 2012; 7:e52350.
14. Barbagallo M, Dominguez LJ, Galioto A, etal. Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. Mol Aspects Med. 2003; 24:39-52.
15. Wolf FI, Trapani V, Simonacci M, Ferré S, Maier JA. Magnesium deficiency and endothelial dysfunction: Is oxidative stress involved? Magnes Res. 2008; 21:58-64.
16. Holzmacher R, Kendziorski C, Michael Hofman R, Jaffery J, Becker B, Djamali A. Low serum magnesium is associated with decreased graft survival in patients with chronic cyclosporin nephrotoxicity. Nephrol Dial Transplant. 2005; 20:1456-1462.
17. Van Laecke S, Nagler EV, Verbeke F, Van Biesen W, Vanholder R. Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease. Am J Med. 2013; 126:825-831.
18. Kanbay M, Yilmaz MI, APetrii M, etal. Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol. 2012; 36:228-237.
19. Ishimura E, Okuno S, Yamakawa T, Inaba M, Nishizawa Y. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res. 2007; 20:237-244.
20. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int. 2013; 85:174-181.
21. Pham PC, Pham PM, Pham SV, Miller JM, Pham PT. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2007; 2:366-373.
22. Pham PC, Pham PM, Pham PA, etal. Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. Clin Nephrol. 2005; 63:429-436.
23. Mather HM, Nisbet JA, Burton GH, etal. Hypomagnesaemia in diabetes. Clin Chim Acta. 1979; 95:235-242.
24. Lopez-Ridaura R, Willett WC, Rimm EB, etal. Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care. 2004; 27:134-140.
25. Kim DJ, Xun P, Liu K, etal. Magnesium intake in relation to systemic inflammation, insulin resistance, and the incidence of diabetes. Diabetes Care. 2010; 33:2604-2610.
26. Corsonello A, Ientile R, Buemi M, etal. Serum ionized magnesium levels in type 2 diabetic patients with microalbuminuria or clinical proteinuria. Am J Nephrol. 2000; 20:187-192.
27. Pham PC, Pham PM, Pham PT, etal. The link between lower serum magnesium and kidney function in patients with diabetes mellitus Type 2 deserves a closer look. Clin Nephrol. 2009; 71:375-379.
28. Del Gobbo LC, Imamura F, Wu JH, de Oliveira Otto MC, Chiuve SE, Mozaffarian D. Circulating and dietary magnesium and risk of cardiovascular disease: A systematic review and meta-analysis of prospective studies. Am J Clin Nutr. 2013; 98:160-173.
29. Kupetsky-Rincon EA, Uitto J. Magnesium: Novel applications in cardiovascular disease-a review of the literature. Ann Nutr Metab. 2012; 61:102-110.
30. Laurant P, Touyz RM. Physiological and pathophysiological role of magnesium in the cardiovascular system: Implications in hypertension. J Hypertens. 2000; 18:1177-1191.
31. Maier JA. Endothelial cells and magnesium: Implications in atherosclerosis. Clin Sci (Lond). 2012; 122:397-407.
32. Ferrè S, Baldoli E, Leidi M, Maier JA. Magnesium deficiency promotes a pro-atherogenic phenotype in cultured human endothelial cells via activation of NFkB. Biochim Biophys Acta. 2010; 1802:952-958.
33. Herzog CA, Asinger RW, Berger AK, etal. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011; 80:572-586.
34. Van Laecke S, Van Biesen W, Vanholder R. Hypomagnesaemia, the kidney and the vessels. Nephrol Dial Transplant. 2012; 27:4003-4010.
35. Rodríguez-Moran M, Guerrero-Romero F. Hypomagnesemia and prehypertension in otherwise healthy individuals. Eur J Intern Med. 2014; 25:128-131. Epub ahead of print.
36. Kisters K, Gröber U. Lowered magnesium in hypertension. Hypertension. 2013; 62:e19.
37. Ma J, Folsom AR, Melnick SL, etal. Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: The ARIC study. Atherosclerosis Risk in Communities Study. J Clin Epidemiol. 1995; 48:927-940.
38. Jee SH, Miller ER 3rd, Guallar E, Singh VK, Appel LJ, Klag MJ. The effect of magnesium supplementation on blood pressure: A meta-analysis of randomized clinical trials. Am J Hypertens. 2002; 15:691-696.
39. Dickinson HO, Nicolson DJ, Campbell F, etal. Magnesium supplementation for the management of essential hypertension in adults. Cochrane Database Syst Rev. 2006; (3):CD004640.
40. Rosanoff A. Magnesium supplements may enhance the effect of antihypertensive medications in stage 1 hypertensive subjects. Magnes Res. 2010; 23:27-40.
41. Maron BA, Leopold JA. Aldosterone receptor antagonists: Effective but often forgotten. Circulation. 2010; 121:934-949.
42. Nadler JL, Buchanan T, Natarajan R, Antonipillai I, Bergman R, Rude R. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension. 1993; 21:1024-1029.
43. Sontia B, Montezano AC, Paravicini T, Tabet F, Touyz RM. Downregulation of renal TRPM7 and increased inflammation and fibrosis in aldosterone-infused mice: Effects of magnesium. Hypertension. 2008; 51:915-921.
44. Yogi A, Callera GE, O'Connor S, etal. Aldosterone signaling through transient receptor potential melastatin 7 cation channel (TRPM7) and its α-kinase domain. Cell Signal. 2013; 25:2163-2175.
45. Yogi A, Callera GE, O'Connor SE, etal. Dysregulation of renal transient receptor potential melastatin 6/7 but not paracellin-1 in aldosterone-induced hypertension and kidney damage in a model of hereditary hypomagnesemia. J Hypertens. 2011; 29:1400-1410.
46. Perticone F, Maio R, Perticone M, etal. Endothelial dysfunction and subsequent decline in glomerular filtration rate in hypertensive patients. Circulation. 2010; 122:379-384.
47. Maier JA, Malpuech-Brugère C, Zimowska W, Rayssiguier Y, Mazur A. Low magnesium promotes endothelial cell dysfunction: Implications for atherosclerosis, inflammation and thrombosis. Biochim Biophys Acta. 2004; 1689:13-21.
48. Paravicini TM, Yogi A, Mazur A, Touyz RM. Dysregulation of vascular TRPM7 and annexin-1 is associated with endothelial dysfunction in inherited hypomagnesemia. Hypertension. 2009; 53:423-429.
49. Miura K, Nakatani T, Asai T, etal. Role of hypomagnesemia in chronic cyclosporine nephropathy. Transplantation. 2002; 73:340-347.
50. Shechter M, Sharir M, Labrador MJ, Forrester J, Silver B, Bairey Merz CN. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation. 2000; 102:2353-2358.
51. Bash LD, Erlinger TP, Coresh J, Marsh-Manzi J, Folsom AR, Astor BC. Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2009; 53:596-605.
52. Tonelli M, Sacks F, Pfeffer M, etal. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int. 2005; 68:237-245.
53. Shogi T, Miyamoto A, Ishiguro S, Nishio A. Enhanced release of IL-1beta and TNF-alpha following endotoxin challenge from rat alveolar macrophages cultured in low-mg(2+) medium. Magnes Res. 2003; 16:111-119.
54. Shogi T, Oono H, Nakagawa M, Miyamoto A, Ishiguro S, Nishio A. Effects of a low extracellular magnesium concentration and endotoxin on IL-1beta and TNF-alpha release from, and mRNA levels in, isolated rat alveolar macrophages. Magnes Res. 2002; 15:147-152.
55. Tejero-Taldo MI, Kramer JH, Mak I, Komarov AM, Weglicki WB. The nerve-heart connection in the pro-oxidant response to Mg-deficiency. Heart Fail Rev. 2006; 11:35-44.
56. Reffelmann T, Ittermann T, Dörr M, etal. Low serum magnesium concentrations predict cardiovascular and all-cause mortality. Atherosclerosis. 2011; 219:280-284.
57. Qu X, Jin F, Hao Y, etal. Magnesium and the risk of cardiovascular events: A meta-analysis of prospective cohort studies. PLoS ONE. 2013; 8:e57720.
58. Misialek JR, Lopez FL, Lutsey PL, etal. Serum and dietary magnesium and incidence of atrial fibrillation in whites and in African Americans-Atherosclerosis Risk in Communities (ARIC) study. Circ J. 2013; 77:323-329.
59. Eichhorn EJ, Tandon PK, DiBianco R, etal. Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: The PROMISE Study. J Am Coll Cardiol. 1993; 21:634-640.
60. Khan AM, Sullivan L, McCabe E, Levy D, Vasan RS, Wang TJ. Lack of association between serum magnesium and the risks of hypertension and cardiovascular disease. Am Heart J. 2010; 160:715-720.
61. Song Y, Manson JE, Cook NR, Albert CM, Buring JE, Liu S. Dietary magnesium intake and risk of cardiovascular disease among women. Am J Cardiol. 2005; 96:1135-1141.
62. Song Y, Ridker PM, Manson JE, Cook NR, Buring JE, Liu S. Magnesium intake, C-reactive protein, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care. 2005; 28:1438-1444.
63. Chiuve SE, Korngold EC, Januzzi JL Jr, Gantzer ML, Albert CM. Plasma and dietary magnesium and risk of sudden cardiac death in women. Am J Clin Nutr. 2011; 93:253-260.
64. Liao F, Folsom AR, Brancati FL. Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 1998; 136:480-490.
65. Hruby A, O'Donnell CJ, Jacques PF, Meigs JB, Hoffmann U, McKeown NM. Magnesium intake is inversely associated with coronary artery calcification: The Framingham Heart Study. JACC Cardiovasc Imaging. 2014; 7:59-69.
66. Zhang W, Iso H, Ohira T, Date C, Tamakoshi A. Associations of dietary magnesium intake with mortality from cardiovascular disease: The JACC study. JACC Study Group. Atherosclerosis. 2012; 221:587-595.
67. Chiuve SE, Sun Q, Curhan GC, etal. Dietary and plasma magnesium and risk of coronary heart disease among women. J Am Heart Assoc. 2013; 2:e000114.
68. Cheung AK, Sarnak MJ, Yan G, etal. Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study. Kidney Int. 2004; 65:2380-2389.
69. Shakeri A, Abdi M, Khosroshahi HT, Fouladi RF. Common carotid artery intima-media thickness and atherosclerotic plaques in carotid bulb in patients with chronic kidney disease on hemodialysis: A case-control study. Pak J Biol Sci. 2011; 14:844-848.
70. Tzanakis I, Pras A, Kounali D, etal. Mitral annular calcifications in haemodialysis patients: A possible protective role of magnesium. Nephrol Dial Transplant. 1997; 12:2036-2037.
71. Meema HE, Oreopoulos DG, Rapoport A. Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int. 1987; 32:388-394.
72. Ari E, Kaya Y, Demir H, Asicioglu E, Keskin S. The correlation of serum trace elements and heavy metals with carotid artery atherosclerosis in maintenance hemodialysis patients. Biol Trace Elem Res. 2011; 144:351-359.
73. Turgut F, Kanbay M, Metin MR, Uz E, Akcay A, Covic A. Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol. 2008; 40:1075-1082.
74. Mortazavi M, Moeinzadeh F, Saadatnia M, Shahidi S, McGee JC, Minagar A. Effect of magnesium supplementation on carotid intima-media thickness and flow-mediated dilatation among hemodialysis patients: A double-blind, randomized, placebo-controlled trial. Eur Neurol. 2013; 69:309-316.
75. Tzanakis I, Virvidakis K, Tsomi A, etal. Intra- and extracellular magnesium levels and atheromatosis in haemodialysis patients. Magnes Res. 2004; 17:102-108.
76. Inagaki O, Syono T, Nakagawa K, Nishian Y, Takenaka Y, Takamitsu Y. Influence of magnesium deficiency on concentration of calcium in soft tissue of uremic rats. Ren Fail. 1996; 18:847-854.
77. Planells E, Llopis J, Perán F, Aranda P. Changes in tissue calcium and phosphorus content and plasma concentrations of parathyroid hormone and calcitonin after long-term magnesium deficiency in rats. J Am Coll Nutr. 1995; 14:292-298.
78. Hashimoto T, Hara A, Ohkubo T, etal. Serum magnesium, ambulatory blood pressure, and carotid artery alteration: The Ohasama study. Am J Hypertens. 2010; 23:1292-1298.
79. Van Laecke S, Maréchal C, Verbeke F, etal. The relation between hypomagnesaemia and vascular stiffness in renal transplant recipients. Nephrol Dial Transplant. 2011; 26:2362-2369.
80. Louvet L, Büchel J, Steppan S, Passlick-Deetjen J, Massy ZA. Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. Nephrol Dial Transplant. 2013; 28:869-878.
81. Massy ZA, Drüeke TB. Magnesium and outcomes in patients with chronic kidney disease: Focus on vascular calcification, atherosclerosis and survival. Clin Kidney J. 2012; 5(Suppl 1):i52-i61.
82. Jablonski KL, Chonchol M. Vascular calcification in end-stage renal disease. Hemodial Int. 2013; 17(Suppl 1):S17-S21.
83. Kircelli F, Peter ME, Sevinc Ok E, etal. Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner. Nephrol Dial Transplant. 2012; 27:514-521.
84. Tamashiro M, Iseki K, Sunagawa O, etal. Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis. 2001; 38:64-69.
85. Srinivasan AR, Niranjan G, Kuzhandai Velu V, Parmar P, Anish A. Status of serum magnesium in type 2 diabetes mellitus with particular reference to serum triacylglycerol levels. Diabetes Metab Syndr. 2012; 6:187-189.
86. Nasri H, Baradaran A. Correlation of serum magnesium with dyslipidemia in maintenance hemodialysis patients. Acta Medica (Hradec Kralove). 2004; 47:263-265.
87. Robles NR, Escola JM, Albarran L, Espada R. Correlation of serum magnesium and serum lipid levels in hemodialysis patients. Nephron. 1998; 78:118-119.
88. Ansari MR, Maheshwari N, Shaikh MA, etal. Correlation of serum magnesium with dyslipidemia in patients on maintenance hemodialysis. Saudi J Kidney Dis Transpl. 2012; 23:21-25.
89. Khatami MR, Mirchi E, Khazaeipour Z, Abdollahi A, Jahanmardi A. Association between serum magnesium and risk factors of cardiovascular disease in hemodialysis patients. Iran J Kidney Dis. 2013; 7:47-52.
90. Saravanan P, Davidson NC. Risk assessment for sudden cardiac death in dialysis patients. Circ Arrhythm Electrophysiol. 2010; 3:553-559.
91. Trinkley KE, Lee Page R 2nd, Lien H, Yamanouye K, Tisdale JE. QT interval prolongation and the risk of torsades de pointes: Essentials for clinicians. Curr Med Res Opin. 2013; 29:1719-1726.
92. Alabd MA, El-Hammady W, Shawky A, Nammas W, El-Tayeb M. QT interval and QT dispersion in patients undergoing hemodialysis: Revisiting the old theory. Nephron Extra. 2011; 1:1-8.
93. Khan AM, Lubitz SA, Sullivan LM, etal. Low serum magnesium and the development of atrial fibrillation in the community: The Framingham Heart Study. Circulation. 2013; 127:33-38.
94. Tezcan UK, Amasyali B, Can I. Increased P wave dispersion and maximum P wave duration after hemodialysis. Ann Noninvasive Electrocardiol. 2004; 9:34-38.
95. Crippa G, Sverzellati E, Giorgi-Pierfranceschi M, Carrara GC. Magnesium and cardiovascular drugs: Interactions and therapeutic role. Ann Ital Med Int. 1999; 14:40-45.
96. Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int. 2004; 66:1212-1220.
97. Kyriazis J, Kalogeropoulou K, Bilirakis L, etal. Dialysate magnesium level and blood pressure. Kidney Int. 2004; 66:1221-1231.
98. Pakfetrat M, Roozbeh Shahroodi J, Malekmakan L, etal. Is there an association between intradialytic hypotension and serum magnesium changes? Hemodial Int. 2010; 14:492-497.
99. Elsharkawy MM, Youssef AM, Zayoon MY. Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates. Hemodial Int. 2006; 10(Suppl 2):S16-S23.
100. Liu F, Zhang X, Qi H, etal. Correlation of serum magnesium with cardiovascular risk factors in maintenance hemodialysis patients-a cross-sectional study. Magnes Res. 2013; 26:100-108.
101. Shin JI, Park SJ, Kim JH. Could intradialytic hypotension be due to low baseline magnesium levels or inflammation in hemodialysis patients? Hemodial Int. 2011; 15:301-302.
102. Ari E, Kaya Y, Demir H, etal. Oxidative DNA damage correlates with carotid artery atherosclerosis in hemodialysis patients. Hemodial Int. 2011; 15:453-459.
103. Pakfetrat M, Malekmakan L, Roozbeh J, Haghpanah S. Magnesium and its relationship to C-reactive protein among hemodialysis patients. Magnes Res. 2008; 21:167-170.
104. Fein P, Suda V, Borawsky C, etal. Relationship of serum magnesium to body composition and inflammation in peritoneal dialysis patients. Adv Perit Dial. 2010; 26:112-115.
105. Yuan J, Zhou J, Chen BC, etal. Magnesium supplementation prevents chronic cyclosporine nephrotoxicity via adjusting nitric oxide synthase activity. Transplant Proc. 2005; 37:1892-1895.
106. Pere AK, Lindgren L, Tuomainen P, etal. Dietary potassium and magnesium supplementation in cyclosporine-induced hypertension and nephrotoxicity. Kidney Int. 2000; 58:2462-2472.
107. Mervaala EM, Pere AK, Lindgren L, etal. Effects of dietary sodium and magnesium on cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats. Hypertension. 1997; 29:822-827.
108. Markell MS, Altura BT, Barbour RL, Altura BM. Ionized and total magnesium levels in cyclosporin-treated renal transplant recipients: Relationship with cholesterol and cyclosporin levels. Clin Sci (Lond). 1993; 85:315-318.
109. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003; 3:178-185.
110. Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int. 2002; 62:1440-1446.
111. Revanur VK, Jardine AG, Kingsmore DB, Jaques BC, Hamilton DH, Jindal RM. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant. 2001; 15:89-94.
112. Barton CH, Vaziri ND, Martin DC, Choi S, Alikhani S. Hypomagnesemia and renal magnesium wasting in renal transplant recipients receiving cyclosporine. Am J Med. 1987; 83:693-699.
113. Navaneethan SD, Sankarasubbaiyan S, Gross MD, Jeevanantham V, Monk RD. Tacrolimus-associated hypomagnesemia in renal transplant recipients. Transplant Proc. 2006; 38:1320-1602.
114. Alexander RT, Hoenderop JG, Bindels RJ. Molecular determinants of magnesium homeostasis: Insights from human disease. J Am Soc Nephrol. 2008; 19:1451-1458.
115. Van Laecke S, Van Biesen W, Verbeke F, De Bacquer D, Peeters P, Vanholder R. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant. 2009; 9:2140-2149.
116. Gupta BK, Glicklich D, Tellis VA. Magnesium repletion therapy improved lipid metabolism in hypomagnesemic renal transplant recipients: A pilot study. Transplantation. 1999; 67:1485-1487.